MA43256B1 - Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique - Google Patents

Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Info

Publication number
MA43256B1
MA43256B1 MA43256A MA43256A MA43256B1 MA 43256 B1 MA43256 B1 MA 43256B1 MA 43256 A MA43256 A MA 43256A MA 43256 A MA43256 A MA 43256A MA 43256 B1 MA43256 B1 MA 43256B1
Authority
MA
Morocco
Prior art keywords
anticholinergic
corticosteroid
dry powder
adrenergic
beta
Prior art date
Application number
MA43256A
Other languages
English (en)
Other versions
MA43256A (fr
Inventor
Francesca Schiaretti
Claudio Cafiero
Leonardo Ortenzi
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43256(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA43256A publication Critical patent/MA43256A/fr
Publication of MA43256B1 publication Critical patent/MA43256B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

L'invention concerne des formulations de poudre sèche pour l'inhalation, qui comprennent une combinaison d'un anticholinergique, d'un agoniste du récepteur adrénergique bêta2 à action prolongée et d'un corticostéroïde, ainsi que leur procédé de préparation.
MA43256A 2015-11-16 2016-11-14 Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique MA43256B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15194660 2015-11-16
PCT/EP2016/077558 WO2017085004A1 (fr) 2015-11-16 2016-11-14 Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Publications (2)

Publication Number Publication Date
MA43256A MA43256A (fr) 2018-09-26
MA43256B1 true MA43256B1 (fr) 2020-05-29

Family

ID=54548062

Family Applications (3)

Application Number Title Priority Date Filing Date
MA43256A MA43256B1 (fr) 2015-11-16 2016-11-14 Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA50488A MA50488B1 (fr) 2015-11-16 2016-11-14 Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA50487A MA50487B1 (fr) 2015-11-16 2016-11-14 Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA50488A MA50488B1 (fr) 2015-11-16 2016-11-14 Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA50487A MA50487B1 (fr) 2015-11-16 2016-11-14 Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Country Status (36)

Country Link
US (4) US10086004B2 (fr)
EP (3) EP3628331B1 (fr)
JP (1) JP6963548B2 (fr)
KR (1) KR20180082443A (fr)
CN (1) CN108289962B (fr)
AR (1) AR106688A1 (fr)
AU (1) AU2016356858B2 (fr)
CA (1) CA3005290A1 (fr)
CL (1) CL2018001298A1 (fr)
CO (1) CO2018005141A2 (fr)
CY (3) CY1123042T1 (fr)
DK (3) DK3377108T3 (fr)
EA (1) EA037716B1 (fr)
ES (3) ES2895687T3 (fr)
GE (1) GEP20207157B (fr)
HR (3) HRP20211598T1 (fr)
HU (3) HUE049751T2 (fr)
IL (1) IL259329B (fr)
LT (3) LT3620176T (fr)
MA (3) MA43256B1 (fr)
MD (3) MD3620176T2 (fr)
ME (1) ME03778B (fr)
MX (1) MX2018005977A (fr)
MY (1) MY186229A (fr)
PE (1) PE20181488A1 (fr)
PH (1) PH12018501022A1 (fr)
PL (3) PL3377108T3 (fr)
PT (3) PT3628331T (fr)
RS (3) RS62404B1 (fr)
SA (1) SA518391570B1 (fr)
SG (2) SG11201804050QA (fr)
SI (3) SI3377108T1 (fr)
TW (1) TWI731891B (fr)
UA (1) UA125019C2 (fr)
WO (1) WO2017085004A1 (fr)
ZA (1) ZA201803168B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018206618A1 (fr) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. Procédé de préparation d'une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
EP3621589B1 (fr) 2017-05-11 2021-07-07 Chiesi Farmaceutici S.p.A. Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
US11433063B1 (en) 2019-03-12 2022-09-06 Belhaven Biopharma, Inc. Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides
US11566036B2 (en) * 2019-03-27 2023-01-31 Kemin Industries, Inc. Methods for preparing metal carboxylates in one-pot reaction
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
WO2021143785A1 (fr) * 2020-01-15 2021-07-22 四川海思科制药有限公司 Composition pharmaceutique de produit à inhaler pour aérosol contenant de l'indacatérol et procédé de préparation de celle-ci
WO2022045995A1 (fr) * 2020-08-28 2022-03-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Procédé de préparation de compositions de poudre sèche pour inhalation
US20220304894A1 (en) * 2021-03-24 2022-09-29 Cmpd Licensing, Llc Drug powderization within vials
WO2023117967A1 (fr) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Formulations en poudre sèche remplies dans un inhalateur présentant une résistance à l'humidité améliorée

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
DK1386630T3 (da) 2002-07-31 2006-09-11 Chiesi Farma Spa Pulverinhalator
AR079726A1 (es) * 2009-12-23 2012-02-15 Chiesi Farma Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
UA118181C2 (uk) * 2012-12-06 2018-12-10 К'Єзі Фармачеутічі С.П.А. Сполуки, які мають активність антагоністів мускаринових рецепторів і агоністів бета-2 адренергічних рецепторів
BR112015012746A2 (pt) * 2012-12-06 2017-07-11 Chiesi Farm Spa compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
PE20212110A1 (es) 2013-07-11 2021-11-04 Chiesi Farm Spa Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion

Also Published As

Publication number Publication date
CY1123042T1 (el) 2021-10-29
TWI731891B (zh) 2021-07-01
US20210177866A1 (en) 2021-06-17
CN108289962B (zh) 2021-09-14
GEP20207157B (en) 2020-10-12
BR112018009807A8 (pt) 2019-02-26
CN108289962A (zh) 2018-07-17
HUE056260T2 (hu) 2022-02-28
CA3005290A1 (fr) 2017-05-26
AU2016356858B2 (en) 2021-06-24
US10772896B2 (en) 2020-09-15
MA43256A (fr) 2018-09-26
SG10201912093YA (en) 2020-02-27
EP3620176A1 (fr) 2020-03-11
MD3377108T2 (ro) 2020-07-31
BR112018009807A2 (pt) 2018-11-06
US20200368252A1 (en) 2020-11-26
RS62506B1 (sr) 2021-11-30
UA125019C2 (uk) 2021-12-29
PH12018501022B1 (en) 2018-12-17
MA50487B1 (fr) 2021-09-30
EP3628331B1 (fr) 2021-08-11
ZA201803168B (en) 2019-07-31
MA50488A (fr) 2021-05-19
CY1124475T1 (el) 2022-07-22
HUE049751T2 (hu) 2020-10-28
PH12018501022A1 (en) 2018-12-17
US10966991B2 (en) 2021-04-06
MA50487A (fr) 2021-04-28
JP6963548B2 (ja) 2021-11-10
ES2891073T3 (es) 2022-01-26
PT3620176T (pt) 2021-09-28
HRP20211598T1 (hr) 2022-01-07
DK3620176T3 (da) 2021-09-20
EP3377108B1 (fr) 2020-02-19
US20170136035A1 (en) 2017-05-18
LT3377108T (lt) 2020-07-10
AU2016356858A1 (en) 2018-05-31
CL2018001298A1 (es) 2018-09-14
CY1124490T1 (el) 2022-07-22
US10086004B2 (en) 2018-10-02
SI3620176T1 (sl) 2021-11-30
HRP20200537T1 (hr) 2020-06-26
IL259329B (en) 2020-10-29
PT3377108T (pt) 2020-04-08
MX2018005977A (es) 2018-08-29
AR106688A1 (es) 2018-02-07
US11628175B2 (en) 2023-04-18
DK3377108T3 (da) 2020-04-20
PE20181488A1 (es) 2018-09-18
SG11201804050QA (en) 2018-06-28
EA037716B1 (ru) 2021-05-13
MY186229A (en) 2021-06-30
DK3628331T3 (da) 2021-09-27
HRP20211600T1 (hr) 2022-01-21
PL3628331T3 (pl) 2021-11-08
MD3628331T2 (ro) 2021-12-31
PL3377108T3 (pl) 2020-09-07
LT3628331T (lt) 2021-11-10
LT3620176T (lt) 2021-11-10
MD3620176T2 (ro) 2021-12-31
EA201890966A1 (ru) 2018-11-30
US20180360849A1 (en) 2018-12-20
KR20180082443A (ko) 2018-07-18
JP2019501876A (ja) 2019-01-24
ES2783855T3 (es) 2020-09-18
SI3628331T1 (sl) 2021-11-30
PL3620176T3 (pl) 2021-11-22
MA50488B1 (fr) 2021-09-30
SI3377108T1 (sl) 2020-05-29
PT3628331T (pt) 2021-10-20
TW201722404A (zh) 2017-07-01
SA518391570B1 (ar) 2022-03-27
WO2017085004A1 (fr) 2017-05-26
RS62404B1 (sr) 2021-10-29
IL259329A (en) 2018-07-31
EP3620176B1 (fr) 2021-08-11
HUE056441T2 (hu) 2022-02-28
EP3628331A1 (fr) 2020-04-01
ES2895687T3 (es) 2022-02-22
EP3377108A1 (fr) 2018-09-26
CO2018005141A2 (es) 2018-09-28
ME03778B (fr) 2021-04-20
RS60171B1 (sr) 2020-05-29

Similar Documents

Publication Publication Date Title
MA43256B1 (fr) Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
BR112015012746A2 (pt) compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
MA38147A1 (fr) Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique
PH12017501424B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CO2018005139A2 (es) Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico
MY196804A (en) Class of bifunctional compounds with quaternary ammonium salt structure
MX2017015047A (es) Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico.
MA48620A (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA38782B1 (fr) Formulation de poudre sèche comportant un anticholinergique, un corticostéroïde et un bêta-adrénergique pour l'administration par inhalation
MA48621A (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
JO3621B1 (ar) مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll